scholarly journals Secondary Cutaneous Diffuse Large B-cell Lymphoma has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-cell Lymphoma, Leg Type

2016 ◽  
Vol 96 (2) ◽  
pp. 245-250 ◽  
Author(s):  
W Lee ◽  
K Won ◽  
C Won ◽  
S Chang ◽  
J Choi ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
International Prognostic Index ◽  
Prognostic Index ◽  
B Cell Lymphoma ◽  
Index Score ◽  
International Prognostic Index Score ◽  
Large B Cell Lymphoma ◽  
Worse Prognosis ◽  
Large B Cell

scholarly journals Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma

2009 ◽  
Vol 150 (44) ◽  
pp. 2019-2026
Author(s):  
Tamás Schneider ◽  
Zsuzsanna Molnár ◽  
Beáta Deák ◽  
Erika Várady ◽  
Erika Tóth ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
International Prognostic Index ◽  
Prognostic Index ◽  
B Cell Lymphoma ◽  
Index Score ◽  
International Prognostic Index Score ◽  
Large B Cell Lymphoma ◽  
Chemotherapeutic Treatment ◽  
Large B Cell

A cyclophosphamid-doxorubicin-vincristin-prednisolon (CHOP-) kezelés több mint 20 éven át standard kezelésnek számított a diffúz nagy B-sejtes lymphomák (DLBCL) elsődleges kezelésében. A CHOP-kezelést célzott immunterápiával, rituximabbal kiegészítve (R-CHOP) jelentős javulás volt elérhető e betegcsoport kezelésében. Magyar betegcsoporton még nem ismert olyan adat, amely a kezelés túlélésre kifejtett hatását vizsgálná. A szerzők célja az R-CHOP és az R-CHOP-like kezelés hatékonyságának elemzése volt. 2002. szeptember és 2005. április között 140 újonnan diagnosztizált, kezeletlen DLBCL-es beteg R-CHOP-kezelését kezdték. A vizsgálatba beválasztás előfeltétele az előrehaladott III–IV. klinikai stádium, vagy I–II. klinikai stádium esetén nagy tumor (>7 cm), és/vagy „B” tünet, illetve extranodalis manifesztáció voltak. Az eredményeket a korábbi években CHOP- és CHOP-like kezelésben részesült 130 beteg adataival vetették össze. A terápiás eredmények minden paramétert tekintve kedvezőbbnek bizonyultak az R-CHOP-kezeltek körében. Az átlagos 44, illetve 52 hónapos követési idő során a teljes remissziós arány 73,6% volt szemben a CHOP-csoportban észlelt 47,7%-kal. Az ötéves teljes túlélés 68,6% vs. 41,0% (RR: 0,4293, CI: 0,2963–0,6221; p < 0,0001), az eseménymentes túlélés 59,8% vs. 33,5% (RR: 0,5038, CI: 0,36,6–0,7038; p < 0,0001), míg a progressziómentes túlélés 64,4% vs. 37,6% (RR: 0,4915, CI: 0,3442–0,7019; p < 0,0001) volt. Mivel a prognosztikus paraméterek az R-CHOP-csoportban valamelyest kedvezőbbek voltak, ezért a Sehn által ajánlott módosított international prognostic index score beosztása alapján képzett betegcsoportok eredményeit is összevetették. Az alcsoportelemzés itt is szignifikáns különbségeket adott. Az ötéves teljes túlélés a jó prognózisú csoportban 74,4% vs. 47,9% (RR: 0,4475, CI: 0,2418–0,8285; p = 0,0084), a rossz prognózisú csoportban 52,0% vs. 28,8% (RR: 0,4989, CI: 0,3098–0,8035; p = 0,003) volt. A nagyon jó prognózisú csoportban a két csoport között statisztikai különbség az ötéves túlélési paraméterekben a már eleve igen nagy terápiás hatás és a kicsi esetszám miatt nem észlelhető (OS és EFS: CHOP: 100% és 62,5% vs. R-CHOP: 90,9% és 87,0%; p = 0,3873 és p = 0,1702). Rituximab hozzáadása a standard CHOP-kezeléshez a terápiás eredmények jelentős javulását eredményezte prognosztikus csoportoktól függetlenül. Az eredmények a nemzetközi irodalmi adatokkal összevethetők.

scholarly journals Circulating long non-coding RNAs HOTAIR, Linc-p21, GAS5 and XIST expression profiles in diffuse large B-cell lymphoma: association with R-CHOP responsiveness

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Mahmoud A. Senousy ◽  
Aya M. El-Abd ◽  
Raafat R. Abdel-Malek ◽  
Sherine M. Rizk
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Expression Profiles ◽  
International Prognostic Index ◽  
Prognostic Index ◽  
B Cell Lymphoma ◽  
Diagnostic Tools ◽  
Large B Cell Lymphoma ◽  
Non Coding Rnas ◽  
Large B Cell

AbstractThe reliable identification of diffuse large B-cell lymphoma (DLBCL)-specific targets owns huge implications for its diagnosis and treatment. Long non-coding RNAs (lncRNAs) are implicated in DLBCL pathogenesis; however, circulating DLBCL-related lncRNAs are barely investigated. We investigated plasma lncRNAs; HOTAIR, Linc-p21, GAS5 and XIST as biomarkers for DLBCL diagnosis and responsiveness to R-CHOP therapy. Eighty-four DLBCL patients and thirty-three healthy controls were included. Only plasma HOTAIR, XIST and GAS5 were differentially expressed in DLBCL patients compared to controls. Pretreatment plasma HOTAIR was higher, whereas GAS5 was lower in non-responders than responders to R-CHOP. Plasma GAS5 demonstrated superior diagnostic accuracy (AUC = 0.97) whereas a panel of HOTAIR + GAS5 superiorly discriminated responders from non-responders by ROC analysis. In multivariate analysis, HOTAIR was an independent predictor of non-response. Among patients, plasma HOTAIR, Linc-p21 and XIST were correlated. Plasma GAS5 negatively correlated with International Prognostic Index, whereas HOTAIR positively correlated with performance status, denoting their prognostic potential. We constructed the lncRNAs-related protein–protein interaction networks linked to drug response via bioinformatics analysis. In conclusion, we introduce plasma HOTAIR, GAS5 and XIST as potential non-invasive diagnostic tools for DLBCL, and pretreatment HOTAIR and GAS5 as candidates for evaluating therapy response, with HOTAIR as a predictor of R-CHOP failure. We provide novel surrogates for future predictive studies in personalized medicine.

scholarly journals Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

2012 ◽  
Vol 30 (28) ◽  
pp. 3452-3459 ◽  
Author(s):  
Nathalie A. Johnson ◽  
Graham W. Slack ◽  
Kerry J. Savage ◽  
Joseph M. Connors ◽  
Susana Ben-Neriah ◽  
...  
Keyword(s):  
Protein Expression ◽  
B Cell ◽  
Cell Lymphoma ◽  
Molecular Subtype ◽  
International Prognostic Index ◽  
Prognostic Index ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Bcl2 Protein ◽  
Large B Cell

Purpose Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated whether expression of MYC protein, with or without BCL2 protein expression, could risk-stratify patients at diagnosis. Patients and Methods We determined the correlation between presence of MYC and BCL2 proteins by immunohistochemistry (IHC) with survival in two independent cohorts of patients with DLBCL treated with R-CHOP. We further determined if MYC protein expression correlated with high MYC mRNA and/or presence of MYC translocation. Results In the training cohort (n = 167), MYC and BCL2 proteins were detected in 29% and 44% of patients, respectively. Concurrent expression (MYC positive/BCL2 positive) was present in 21% of patients. MYC protein correlated with presence of high MYC mRNA and MYC translocation (both P < .001), but the latter was less frequent (both 11%). MYC protein expression was only associated with inferior overall and progression-free survival when BCL2 protein was coexpressed (P < .001). Importantly, the poor prognostic effect of MYC positive/BCL2 positive was validated in an independent cohort of 140 patients with DLBCL and remained significant (P < .05) after adjusting for presence of high-risk features in a multivariable model that included elevated international prognostic index score, activated B-cell molecular subtype, and presence of concurrent MYC and BCL2 translocations. Conclusion Assessment of MYC and BCL2 expression by IHC represents a robust, rapid, and inexpensive approach to risk-stratify patients with DLBCL at diagnosis.

scholarly journals Diffuse large B-cell lymphoma: A single-institution experience of patient outcomes.

2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 271-271
Author(s):  
Ryan James Chan ◽  
Rasna Gupta ◽  
Sindu Mary Kanjeekal ◽  
Mohammed Jarrar ◽  
Amin Kay ◽  
...  
Keyword(s):  
British Columbia ◽  
B Cell ◽  
Cell Lymphoma ◽  
International Prognostic Index ◽  
Prognostic Index ◽  
B Cell Lymphoma ◽  
Canadian Province ◽  
Large B Cell Lymphoma ◽  
Cancer Program ◽  
Large B Cell

271 Background: The Windsor Regional Cancer Program (WRCP) was determined to have consistently been a top performer in time to treatment of diffuse large B cell lymphoma in this Canadian province (http://www.csqi.on.ca/by_type_of_cancer/lymphoma/lymphoma_treatment/). We endeavored to determine whether faster time to diagnosis and treatment for diffuse large B-cell lymphoma (DLBCL) influenced the IPI score (International Prognostic Score), thereby predicting an improved clinical outcome in these presenting patients. Methods: The WRCP services a catchment area of 650,000 people. A retrospective chart review was conducted for patients diagnosed with DLBCL at the Windsor Regional Cancer Program (WRCP) between 2006-2012. Information collected included the five factors for scoring by the International Prognostic Index (IPI) – age, performance status, LDH, stage, and number of extranodal sites – chemotherapy regimen, relapses, existence of second malignancies, cause of death, and dates of diagnosis, last follow-up, and death. We analyzed the relationship between prognostic factors and these clinical outcomes, and also compared the IPI scores for this cohort of patients against a similar population in another Canadian province, British Columbia. Results: It is established that compared to other cancer centres in Ontario, the WRCP is consistently reporting a shorter diagnosis to treatment metric when compared to their counterparts in Ontario, Canada. When compared to historical Canadian data, presenting IPI scores for DLBCL patients were lower on average for patients treated at the WRCP than those reported in British Columbia, Canada by Sehn et al. [Sehn, L. H., et al. (2007). The revised International Prognostic Index is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109(5), 1857-1861.]. Conclusions: A lower presenting IPI score is known to be correlated improved lymphoma related outcome. With attention to the metric of diagnosis to treatment < 30 days for diffuse large B cell lymphoma, we expect an improved lymphoma related outcome for our patients. We recommend ongoing attention to this metric, in order to improve outcomes for our patients.

Sign in / Sign up

Export Citation Format

Share Document